The largest database of trusted experimental protocols

Trevo retriever

Manufactured by Stryker
Sourced in Ireland

The Trevo Retriever is a medical device designed for the mechanical removal of blood clots from the brain during an ischemic stroke. It is intended for use in the revascularization of patients with acute ischemic stroke.

Automatically generated - may contain errors

4 protocols using trevo retriever

1

Mechanical Thrombectomy for Acute Ischemic Stroke

Check if the same lab product or an alternative is used in the 5 most similar protocols
All consecutive acute ischemic stroke patients with large-vessel occlusion treated by mechanical thrombectomy at a single academic institution between August 2002 and October 2012 were identified from a prospectively maintained database. Patients treated with thrombectomy were either ineligible for IV tPA or refractory to thrombolysis after receiving IV tPA within 4.5 h of stroke onset.3 (link),19 (link) The mechanical clot retrieval devices included Merci Retriever (Stryker neurovascular, Mountain View, CA), Penumbra System (Penumbra, Inc., Alameda, CA), stent retriever with Solitaire FR device (Covidien/eV3, Dublin, Ireland), or Trevo Retriever (Stryker neurovascular).
Magnetic resonance imaging (MRI) before thrombectomy was routinely performed in all patients without selection biases unless contraindicated. Patients also typically underwent follow-up magnetic resonance (MR) within 48 h after thrombectomy. The multimodal MRI protocol included diffusion-weighted imaging, perfusion-weighted imaging, T2∗ gradient-recall echo (GRE), and fluid-attenuated inversion recovery (FLAIR) sequences. We included patients who had serial T2∗ GRE before and 48 h after thrombectomy. The local institutional review board of University of California at Los Angeles approved the study. Informed consent was obtained from the patient or their representative.
+ Open protocol
+ Expand
2

Trevo Retriever Registry: Real-World Data

Check if the same lab product or an alternative is used in the 5 most similar protocols
Post-hoc analysis of a prospective multicentre post-market registry (the Trevo Retriever Registry; ClinicalTrials.gov identifier: NCT02040259). The Trevo Retriever Registry is a prospective, open-label, consecutive enrolment, multi-center, international registry aiming to collect real world performance data of the Trevo Retriever (Stryker, Fremont, CA) which is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing AIS (10) .
+ Open protocol
+ Expand
3

Efficacy of Mechanical Thrombectomy Devices

Check if the same lab product or an alternative is used in the 5 most similar protocols
We analyzed data from the Multi MERCI, TREVO, and TREVO 2 trials, in which the Merci Retriever (Stryker Neurovascular, Mountain View, CA) and the Trevo Retriever (Stryker Neurovascular) were used.4 (link),6 (link),8 (link) The databases of all 3 trials were maintained at Stryker Neurovascular. Appropriate institutional review board or ethics committees approvals were obtained by participating centers in all 3 trials. All 3 trials enrolled patients with acute ischemic stroke who were either ineligible for or refractory to IV tPA. Endovascular thrombectomy therapy was initiated within 8 hours of symptom onset.
All 3 trials included patients with angiographically confirmed intracranial vessel occlusion in both anterior and posterior circulations. All patients were older than 18 years with National Institutes of Health Stroke Scale (NIHSS) score of greater than 8. The TREVO and TREVO 2 trials had age limit of 85 years and NIHSS score upper limit of 30 and 29, respectively. In the Multi MERCI trial, IV tPA was allowed within 3 hours after symptom onset. A 4.5-hour time window was used for IV tPA in the TREVO and TREVO 2 trials.
+ Open protocol
+ Expand
4

Thrombectomy Devices for Acute Stroke

Check if the same lab product or an alternative is used in the 5 most similar protocols
Interventionalists were pre-approved based on training and post-training experience as previously described3 (link). Interventionalists could use any FDA approved device for thrombectomy (approved for use within an 8-hour window following stroke onset and used in the DEFUSE 3 study with an FDA investigational device exemption). The devices used were the Trevo Retriever (Stryker Neurovascular, Fremont CA), the Solitaire Revascularization Device (Medtronic, Irvine, CA), Covidien MindFrame Capture Revascularization Device (Medtronic), and the Penumbra Suction Thrombectomy system (Penumbra, Alameda, CA).
The interventionalist could utilize any device or combination of devices in the ICA or MCA M1 segment. They could also use the devices to remove thrombus from MCA M2 segments. If the interventionalists encountered severe common or proximal ICA stenosis or occlusion, they could also perform angioplasty or stenting with FDA approved devices. Adjuvant intraarterial thrombolytic agents were prohibited in DEFUSE 3.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!